Marksans Pharma gets EIR from US FDA for New York unit
In a regulatory filing, the company announced "receipt of the EIR from US Food and Drug Administration (US FDA) in respect of inspection of company's manufacturing facility Time-Cap Laboratories located at Farmingdale, New York, USA carried out from December 5, 2019 to December 18, 2019"
Marksans Pharma said it has received an establishment inspection report (EIR) from the US health regulator for company’s manufacturing facility in the US.
In a regulatory filing, the company announced “receipt of the EIR from US Food and Drug Administration (US FDA) in respect of inspection of company’s manufacturing facility Time-Cap Laboratories located at Farmingdale, New York, USA carried out from December 5, 2019 to December 18, 2019”.
- Advertisement -